A Dose-Ranging Study of 50 µg to 100 µg LSD in Healthy Volunteers
This Phase I study explored the safety, tolerability, pharmacokinetics, and pharmacodynamics of low doses of Lysergic Acid Diethylamide (LSD) ranging from 50 µg to 100 µg in healthy volunteers (n=32).
Details
Two-part study in healthy volunteers: Part 1 was an open-label dose-escalation (50, 75, 100 µg) in hallucinogen-experienced subjects; Part 2 was a double-blind, randomised study including a placebo-controlled crossover and a sequential escalation group in hallucinogen‑naïve subjects.
Part 2 participants received either placebo then 75 µg or 50 µg then 75 µg with doses separated by at least 7 days; assessments included cognitive tasks, PK sampling, and follow-ups at day after, 1 week and 1 month.
Outcomes focussed on safety, tolerability, pharmacokinetics and pharmacodynamics of low-dose LSD.